Iovance Biotherapeutics, Inc. (IOVA) financial statements (2020 and earlier)

Company profile

Business Address 999 SKYWAY ROAD
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:3073861451671044520
Cash and cash equivalents1482145107144520
Short-term investments293  6070  
Other undisclosed cash, cash equivalents, and short-term investments 304 020  
Prepaid expense      0
Other undisclosed current assets98943000
Total current assets:3164751491701044520
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment9322220
Other noncurrent assets334    
Other undisclosed noncurrent assets5      
Total noncurrent assets:28562220
TOTAL ASSETS:3454811551721064720
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3214105220
Accounts payable16311110
Accrued liabilities16129410 
Debt7      
Due to related parties    00 
Other undisclosed current liabilities      2
Total current liabilities:3914105222
Noncurrent Liabilities
Long-term debt and lease obligation4      
Operating lease, liability4
Liabilities, other than long-term debt20     
Deferred rent credit 0
Other liabilities2      
Total noncurrent liabilities:70     
Total liabilities:4615105222
Stockholders' equity
Stockholders' equity attributable to parent, including:2994661451671044518
Preferred stock     00
Common stock0000000
Additional paid in capital86983939532420812182
Accumulated other comprehensive income (loss)0(0) 00  
Accumulated deficit(571)(373)(249)(157)(104)(77)(65)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:2994661451671044518
TOTAL LIABILITIES AND EQUITY:3454811551721064720

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:    (4)  
Operating expenses(207)(128)(93)(54)(28)(12)(23)
Other undisclosed operating income    4  
Operating loss:(207)(128)(93)(54)(28)(12)(23)
Nonoperating income (expense)951100(3)
Investment income, nonoperating9511   
Other nonoperating income (expense)    00(3)
Interest and debt expense     0 
Loss before gain (loss) on sale of properties:(198)(124)(92)(53)(28)(12)(25)
Other undisclosed net loss     (0) 
Net loss attributable to parent:(198)(124)(92)(53)(28)(12)(25)
Preferred stock dividends and other adjustments   (49)  8
Other undisclosed net loss available to common stockholders, basic      (17)
Net loss available to common stockholders, diluted:(198)(124)(92)(102)(28)(12)(34)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(198)(124)(92)(53)(28)(12)(25)
Comprehensive loss:(198)(124)(92)(53)(28)(12)(25)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)(0)(0)0  
Comprehensive loss, net of tax, attributable to parent:(197)(124)(92)(53)(28)(12)(25)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: